Zoetis receives EU approval for canine atopic dermatitis therapy Cytopoint

Animal Health Supplier News

Zoetis has announced that its new canine atopic dermatitis therapy Cytopoint has been approved by the European Commission.

The drug becomes the first monoclonal antibody therapy approved for European veterinary use, and is indicated to treat clinical signs associated with atopic dermatitis in dogs of any age weighing three kg or more.

“Zoetis has received European regulatory approval for Cytopoint, a new treatment for atopic dermatitis in dogs.“

Cytopoint targets and neutralises canine interleukin-31, a key protein involved in triggering itchiness in dogs, and is administered by injection once monthly to provide fast and long-lasting relief from itching and the inflammation and lesions it causes.

It has also been shown to be safe for use in dogs of any age, even those with concomitant diseases, and can be used alongside many common medications, including vaccines.

Dr Catherine Knupp, executive vice-president and president for research and development at Zoetis, said: "As the first such therapy to provide relief from atopic dermatitis, we are once again using our science and focus on our customers' most pressing challenges to find solutions for an area of unmet need in animal health."

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Animal Health
Return to news

Tags